Osimertinib Re-challenge for EGFR-mutant NSCLC after  Osimertinib-induced Interstitial Lung Disease: A Case Report

Osimertinib Re-challenge for EGFR-mutant NSCLC after  Osimertinib-induced Interstitial Lung Disease: A Case Report

Osimertinib-induced interstitial lung disease (ILD) is an uncommon, but fatal pulmonary toxicity in some patients. We report a case of a 64-year-old male with stage IV adeno-non-small cell lung cancer (NSCLC) harboring an exon 19 deletion in the epidermal growth factor receptor (EGFR) treated with o...

Full description

Bibliographic Details
Main Authors:	Junjie GU, Fan BAI, Lan SONG, Yingyi WANG
Format:	Article
Language:	zho
Published:	Chinese Anti-Cancer Association; Chinese Antituberculosis Association 2021-11-01
Series:	Chinese Journal of Lung Cancer
Subjects:	epidermal growth factor receptor interstitial lung disease lung neoplasms osimertinib
Online Access:	http://dx.doi.org/10.3779/j.issn.1009-3419.2021.102.39

Similar Items

Brief Report: Risk of Recurrent Interstitial Lung Disease From Osimertinib Versus Erlotinib Rechallenge After Symptomatic Osimertinib-Induced Interstitial Lung Disease
by: Molly S.C. Li, M.B.B.S., et al.
Published: (2024-04-01)

Osimertinib Improves overall survival of EGFR-mutant NSCLC patients with leptomeningeal metastases
by: Qiuyue Ye, et al.
Published: (2023-05-01)

The Role of Neutrophil-to-Lymphocyte Ratio in Advanced EGFR-Mutant NSCLC Patients Treated with First-Line Osimertinib
by: Chen KC, et al.
Published: (2023-05-01)

Efficacy of Osimertinib Combined with Bevacizumab in Advanced Non-small Cell  Lung Cancer Patients with Acquired EGFR T790M Mutation
by: Yanfei GU, et al.
Published: (2022-12-01)

Impact of sequential therapy with osimertinib on the overall survival in patients with EGFR-mutant non-small cell lung cancer
by: Minehiko Inomata, et al.
Published: (2022-03-01)

Severe Drug-Induced Interstitial Lung Disease After Administration of Osimertinib as Adjuvant Treatment for Resected EGFR-Mutated NSCLC: A Case Report
by: Sho Mitsuya, MD, et al.
Published: (2024-02-01)

Clinical case of long-term use of osimertinib in the treatment of EGFR mutation-positive lung adenocarcinoma
by: Svetlana V. Odintsova, et al.
Published: (2020-07-01)

Overcoming acquired resistance of EGFR‐mutant NSCLC cells to the third generation EGFR inhibitor, osimertinib, with the natural product honokiol
by: Hongjing Zang, et al.
Published: (2020-04-01)

Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC
by: Silvia La Monica, et al.
Published: (2019-05-01)

Osimertinib Rechallenge With Bevacizumab vs. Chemotherapy Plus Bevacizumab in EGFR-Mutant NSCLC Patients With Osimertinib Resistance
by: Qingli Cui, et al.
Published: (2022-01-01)

Distinct Progression and Efficacy of First-Line Osimertinib Treatment According to Mutation Subtypes in Metastatic NSCLC Harboring EGFR Mutations
by: Yuki Takeyasu, MD, et al.
Published: (2024-02-01)

Successful retreatment with osimertinib after osimertinib-induced acute pulmonary embolism in a patient with lung adenocarcinoma: A case report
by: Takayuki Shiroyama, et al.
Published: (2017-01-01)

Heart Failure Associated With the Epidermal Growth Factor Receptor Inhibitor Osimertinib
by: Andrew J. Piper-Vallillo, MD, et al.
Published: (2020-03-01)

Impact of T790M Mutation Status on Later-Line Osimertinib Treatment in Non-Small Cell Lung Cancer Patients
by: Yan-Jei Tang, et al.
Published: (2022-10-01)

Successful response to first-line treatment with osimertinib for choroidal metastasis from EGFR-mutated non-small-cell lung cancer
by: Matthew G. Field, et al.
Published: (2022-06-01)

Osimertinib in NSCLC: Real-World Data From New Zealand
by: Yeojeong Jane So, MbChB, FRACP, et al.
Published: (2020-06-01)

Efficacy of the CDK4/6 Dual Inhibitor Abemaciclib in EGFR-Mutated NSCLC Cell Lines with Different Resistance Mechanisms to Osimertinib
by: Silvia La Monica, et al.
Published: (2020-12-01)

EGFR‐mutant lung adenocarcinoma associated with antisynthetase syndrome successfully treated with osimertinib
by: Reina Hara, et al.
Published: (2021-05-01)

Efficacy of Osimertinib in NSCLC Harboring Uncommon EGFR L861Q and Concurrent Mutations: Case Report and Literature Review
by: Ruiting Lin, et al.
Published: (2021-09-01)

Survival benefit of combinatorial osimertinib rechallenge and entrectinib in an EGFR‐mutant NSCLC patient with acquired LMNA‐NTRK1 fusion following osimertinib resistance
by: Jiao‐Li Wang, et al.
Published: (2022-11-01)

Impact of pre‐existing interstitial lung abnormal shadow on lung injury development and severity in patients of non‐small cell lung cancer treated with osimertinib
by: Ryota Shibaki, et al.
Published: (2022-10-01)

Pretreatment Neutrophil-to-Lymphocyte Ratio and Smoking History as Prognostic Factors in Advanced Non–Small Cell Lung Cancer Patients Treated with Osimertinib
by: Ji Young Park, et al.
Published: (2022-04-01)

A Phase I Trial of Dasatinib and Osimertinib in TKI Naïve Patients With Advanced EGFR-Mutant Non-Small-Cell Lung Cancer
by: Chul Kim, et al.
Published: (2021-09-01)

Successful Rechallenge with Osimertinib following Osimertinib-Induced Ventricular Tachycardia: A Case Report
by: Zentaro Saito, et al.
Published: (2023-10-01)

Analyses of CNS Response to Osimertinib in Patients with T790M-Positive Advanced NSCLC from ASTRIS Korean Subset, Open-Label Real-World Study
by: Beung-Chul Ahn, et al.
Published: (2021-07-01)

Systemic and Intracranial Efficacy of Osimertinib in EGFR L747P-Mutant NSCLC: Case Report
by: David E. Gerber, MD, et al.
Published: (2022-03-01)

Efficacy of osimertinib in epidermal growth factor receptor-mutated non-small-cell lung cancer patients with pleural effusion
by: Hiroshi Nokihara, et al.
Published: (2022-06-01)

Pneumatosis intestinalis induced by osimertinib in a patient with lung adenocarcinoma harbouring epidermal growth factor receptor gene mutation with simultaneously detected exon 19 deletion and T790 M point mutation: a case report
by: Yuki Nukii, et al.
Published: (2019-02-01)

Analysis of adverse drug reactions of Osimertinib in the 2nd‐line treatment of EGFR mutant advanced nonsmall cell lung cancer
by: Yingying Jiang, et al.
Published: (2022-06-01)

Intracranial Outcomes of De Novo Brain Metastases Treated With Osimertinib Alone in Patients With Newly Diagnosed EGFR-Mutant NSCLC
by: Brandon S. Imber, MD, MA, et al.
Published: (2023-12-01)

Mixed response to osimertinib and the beneficial effects of additional local therapy
by: Yuki Shinno, et al.
Published: (2019-04-01)

Acquired Drug Resistance Mechanism of Osimertinib in the Targeted Therapy of Non-small Cell Lung Cancer
by: Zitong ZHAO, et al.
Published: (2020-04-01)

Clinical efficacy of osimertinib in EGFR-mutant non-small cell lung cancer with distant metastasis
by: Soei Gen, et al.
Published: (2022-06-01)

Osimertinib for the first-line treatment of EGFR-positive non-small cell lung cancer
by: Elena V Reutova, et al.
Published: (2019-09-01)

Osimertinib-associated ashy dermatosis–like hyperpigmentation
by: Pattamon Lertpichitkul, MD, et al.
Published: (2020-02-01)

Afatinib + bevacizumab combination therapy in EGFR‐mutant NSCLC patients with osimertinib resistance: Protocol of an open‐label, phase II, multicenter, single‐arm trial
by: Nobuaki Kobayashi, et al.
Published: (2020-08-01)

PRMT-1 and p120-Catenin as EMT Mediators in Osimertinib Resistance in NSCLC
by: Kavya Sri Racherla, et al.
Published: (2023-07-01)

A Real-World Analysis of Immune Checkpoint Inhibitor-Based Therapy After Osimertinib Treatment in Patients With EGFR-Mutant NSCLC
by: Kenji Morimoto, MD, PhD, et al.
Published: (2022-09-01)

Identification of a Rare EGFR T790I Mutation in Lung Adenocarcinoma Sensitive to Osimertinib
by: Yu Wang, et al.
Published: (2021-10-01)

Osimertinib regressed an EGFR-mutant lung-adenocarcinoma bone-metastasis mouse model and increased long-term survival
by: Takashi Higuchi, et al.
Published: (2020-10-01)